Tiziana life sciences announces foralumab dosing of four new patients in the expanded access program for multiple sclerosis

New york, nov. 30, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-spms) in the brigham and women's hospital, a founding member of mass general brigham healthcare system expanded access (ea) program. a total of ten patients are now being followed in the ea program.
TLSA Ratings Summary
TLSA Quant Ranking